Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer
Authors:
- Zsuzsanna Bago-HorvathZBZsuzsanna Bago-Horvath
- Anna BerghoffABAnna Berghoff
- Catharina DeVriesCDCatharina DeVries
- Ursula PluschnigUPUrsula Pluschnig
- Peter DubskyPDPeter Dubsky
- Margaretha RudasMRMargaretha Rudas
- Robert M. MaderRMRobert M. Mader
- Andrea RottenfusserARAndrea Rottenfusser
- Florian FitzalFFFlorian Fitzal
- Michael GnantMichael Gnant
- Christoph C. ZielinskiCZChristoph C. Zielinski
- 1 September 2012
- journal article
- clinical trial
- Published by Elsevier in European Journal of Cancer
- Vol. 48 (13) , 1932-1938
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal womenEuropean Journal of Cancer, 2010
- Activity of fulvestrant in HER2-overexpressing advanced breast cancerAnnals of Oncology, 2009
- Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST StudyJournal of Clinical Oncology, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECTJournal of Clinical Oncology, 2008
- Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancerEuropean Journal of Cancer, 2007
- Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancerEndocrine-Related Cancer, 2005
- Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal womenCancer, 2003
- A randomized, multicenter prospective trial assessing long‐acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinomaCancer, 2002
- Similarities and distinctions in the mode of action of different classes of antioestrogens.Endocrine-Related Cancer, 2000